Sleeping in low light can reverse DME changes

Article

Patients sleeping in a low-lit room may find that the changes in diabetic macular oedema (DME) are reversed.

Patients sleeping in a low-lit room may find that the changes in diabetic macular oedema (DME) are reversed, claims a study in Eye.

Dr G.B. Arden et al., School of Community and Health Sciences, City University, London, UK, conducted an investigation on 40 patients with mild non-proliferative diabetic retinopathy (DR) and early, untreated non-sight threatening DME. For six months all patients slept with a mask that illuminated the eyelid of a single closed eye with a 505 nm light.

The exclusion criteria were the presence of any concomitant eye disease and the primary outcome was the change in OCT retinal thickness where oedema was present.

Of the 40 patients observed, 34 completed the investigation. For study and fellow eyes the mean baseline OCT macular cube thickness was equivalent. It was found that the study eyes presented with a greater thickness in the central subfield zone 1 compared to the fellow eyes.

Intraretinal cysts were found in 28 eyes, compared to 9 found in the fellow eyes. Only 19 study eyes presented with cysts at 6 months, whilst 20 fellow eyes had cysts. In study eyes the worst affected ETDRS zone and the central subfield zone 1 experienced a reduction in thickness by 12μm.

In study eyes visual acuity, achromatic contrast sensitivity and microperimetric thresholds improved and in the fellow eyes they deteriorated.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.